Effectiveness of different vaccine formulations against vibriosis caused by Vibrio vulnificus serovar E (biotype 2) in European eels Anguilla anguilla
Effectiveness of different vaccine formulations against vibriosis caused by Vibrio vulnificus serovar E (biotype 2) in European eels Anguilla anguilla
复制标题
DOI：
10.3354/dao043091
复制
发表时间：
2000-11-14
影响因子：
1.4
通讯作者：
Amaro, C
中科院分区：
文献类型：
--
作者：
Collado, R;Fouz, B;Amaro, C
由创伤弧菌 E 血清型（生物型 2）引起的弧菌病是欧洲养殖的欧洲鳗鱼死亡的主要原因之一。这项研究的主要目的是开发针对这种病原体的疫苗和疫苗接种程序。为此，我们在受控实验室条件下使用不同的递送途径（注射和浸泡）在鳗鱼上测试了几种疫苗配方（含有或不含类毒素的灭活全细胞、来自胶囊化和非胶囊化菌株的灭活细胞外产物、减毒活疫苗和纯化脂多糖 [LPS]）。为了研究免疫反应，我们评估了粘液和血清中的抗体滴度和杀菌/抑菌活性。为了评估保护作用，我们计算了病原体腹腔 (i.p.) 注射和浴攻击后的相对存活百分比 (RPS)。总体结果表明：（1）荚膜抗原似乎对于保护性免疫至关重要； (2) 通过腹腔注射注射疫苗可提供最高的保护。注射; (3)需要升压器才能实现良好的浸泡保护； (4) 在疫苗中添加类毒素可将保护作用增强至最佳水平（RPS 值约为 70% 至 100%，具体取决于递送途径）； (5)血清和粘液中的保护作用取决于给药途径，并且似乎与特异性抗体的产生有关。
Vibriosis due to Vibrio vulnificus serovar E (biotype 2) is one of the main causes of mortality in European eels cultured in Europe. The main objective of this study was to develop a vaccine and a vaccination procedure against this pathogen. With this aim, we tested several vaccine formulations (inactivated whole-cells with and without toxoids-inactivated extracellular products-from capsulated and uncapsulated strains, attenuated live vaccines and purified lipopolysaccharide [LPS]) on eels maintained under controlled laboratory conditions using different delivery routes (injection and immersion). To study the immune response we estimated antibody titers and bactericidal/bacteriostatic activity in mucus and serum. To evaluate protection, we calculated the relative percent survival (RPS) after intraperitoneal (i.p.) injection and bath challenge of the pathogen. The overall results indicate that: (1) capsular antigens seem to be essential for protective immunization; (2) vaccines confer the highest protection when administered by i.p. injection; (3) booster is needed to achieve good protection by immersion; (4) enriching the vaccine with toxoids enhances protection to optimal levels (RPS values around 70 to 100 %, depending on the delivery route); and (5) the protective effect in serum and mucus depends on the route of administration and seems to be related to the production of specific antibodies.